Drinkable preparation of theracurmin exhibits high absorption efficiency-a single-dose, double-blind, 4-way crossover study

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 11, 2013, Pages 1708-1714

  Morimoto, Tatsuya ^a,b,f   Sunagawa, Yoichi ^a,f   Katanasaka, Yasufumi ^a,f   Hirano, Sae ^a   Namiki, Masatoshi ^a   Watanabe, Yuichi ^a   Suzuki, Hidetoshi ^a   Doi, Osamu ^b   Suzuki, Kiyomi ^b   Yamauchi, Miyuki ^b   Yokoji, Tsunehiro ^b   Miyoshi Morimoto, Eriko ^b   Otsuka, Yoshihiko ^c   Hamada, Tomoko ^c   Imaizumi, Atsushi ^c   Nonaka, Yuji ^d   Fuwa, Takashi ^d   Teramoto, Takanori ^d   Kakeya, Hideaki ^e   Wada, Hiromichi ^f   Hasegawa, Koji ^f   more..

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b SHIZUOKA GENERAL HOSPITAL   (Japan)

^c Theravalues Corporation   (Japan)

^d SUNTORY LTD   (Japan)

^e KYOTO UNIVERSITY   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

Author keywords

Curcumin; Drinkable preparation; Human; Plasma level; Theracurmin

Indexed keywords

CURCUMIN; THERACURMIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BEVERAGE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG RETENTION; FEMALE; HUMAN; HUMAN EXPERIMENT; JAPAN; MALE; NORMAL HUMAN; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABSORPTION; ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; BEVERAGES; CROSS-OVER STUDIES; CURCUMIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; YOUNG ADULT;

EID: 84888594853     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00150     Document Type: Article

References (49)

1. Epstein J, Sanderson IR, Macdonald TT. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br. J. Nutr., 103, 1545-1557 (2010).
2. Shimatsu A, Kakeya H, Imaizumi A, Morimoto T, Kanai M, Maeda S. Clinical application of "curcumin," a multi-functional substance. Anti-Aging Med., 9, 75-83 (2012).
3. Esatbeyoglu T, Huebbe P, Ernst IM, Chin D, Wagner AE, Rimbach G. Curcumin - From molecule to biological function. Angew. Chem. Int. Ed. Engl., 51, 5308-5332 (2012).
4. Selvam R, Subramanian L, Gayathri R, Angayarkanni N. The antioxidant activity of turmeric (Curcuma longa). J. Ethnopharmacol., 47, 59-67 (1995).
5. Ruby AJ, Kuttan G, Babu KD, Rajasekharan KN, Kuttan R. Antitumour and antioxidant activity of natural curcuminoids. Cancer Lett., 94, 79-83 (1995).
6. Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. Adv. Exp. Med. Biol., 595, 105-125 (2007).
7. Rao TS, Basu N, Siddiqui HH. Anti-inflammatory activity of curcumin analogues. Indian J. Med. Res., 75, 574-578 (1982).
8. Negi PS, Jayaprakasha GK, Jagan Mohan Rao L, Sakariah KK. Antibacterial activity of turmeric oil: A byproduct from curcumin manufacture. J. Agric. Food Chem., 47, 4297-4300 (1999).
9. Wuthi-udomlert M, Grisanapan W, Luanratana O, Caichompoo W. Antifungal activity of Curcuma longa grown in Thailand. Southeast Asian J. Trop. Med. Public Health, 31 (Suppl. 1), 178-182 (2000).
10. López-Lázaro M. Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol. Nutr. Food Res., 52 (Suppl 1), S103-S127 (2008).
11. Das L, Vinayak M. Anti-carcinogenic action of curcumin by activation of antioxidant defence system and inhibition of NF-kappaB signalling in lymphoma-bearing mice. Biosci. Rep., 32, 161-170 (2012).
12. Morimoto T, Sunagawa Y, Kawamura T, Takaya T, Wada H, Nagasawa A, Komeda M, Fujita M, Shimatsu A, Kita T, Hasegawa K. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J. Clin. Invest., 118, 868-878 (2008).
13. Sunagawa Y, Morimoto T, Wada H, Takaya T, Katanasaka Y, Kawamura T, Yanagi S, Marui A, Sakata R, Shimatsu A, Kimura T, Kakeya H, Fujita M, Hasegawa K. A natural p300-specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensin converting enzyme inhibitor exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats. Circ. J., 75, 2151-2159 (2011).
14. Thiyagarajan M, Sharma SS. Neuroprotective effect of curcumin in middle cerebral artery occlusion induced focal cerebral ischemia in rats. Life Sci., 74, 969-985 (2004).
15. Shankar TN, Shantha NV, Ramesh HP, Murthy IA, Murthy VS. Toxicity studies on turmeric (Curcuma longa): acute toxicity studies in rats, guineapigs and monkeys. Indian J. Exp. Biol., 18, 73-75 (1980).
16. Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z, Brenner DE. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol. Biomarkers Prev., 17, 1411-1417 (2008).
17. Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and pharmacodynamics of curcumin. Adv. Exp. Med. Biol., 595, 453-470 (2007).
18. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol. Pharm., 4, 807-818 (2007).
19. Fang M, Jin Y, Bao W, Gao H, Xu M, Wang D, Wang X, Yao P, Liu L. In vitro characterization and in vivo evaluation of nanostructured lipid curcumin carriers for intragastric administration. Int. J. Nanomedicine, 7, 5395-5404 (2012).
20. Grynkiewicz G, lifirski P. Curcumin and curcuminoids in quest for medicinal status. Acta Biochim. Pol., 59, 201-212 (2012).
21. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med., 64, 353-356 (1998).
22. Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, Kakeya H, Fujita M, Hasegawa K, Morimoto T. Innovative preparation of curcumin for improved oral bioavailability. Biol. Pharm. Bull., 34, 660-665 (2011).
23. Sunagawa Y, Wada H, Suzuki H, Sasaki H, Imaizumi A, Fukuda H, Hashimoto T, Katanasaka Y, Shimatsu A, Kimura T, Kakeya H, Fujita M, Hasegawa K, Morimoto T. A novel drug delivery system of oral curcumin markedly improves efficacy of treatment for heart failure after myocardial infarction in rat. Biol. Pharm. Bull., 35, 139-144 (2012).
24. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A, Maitra A. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): A novel strategy for human cancer therapy. J. Nanobiotechnology, 5, 3 (2007).
25. Tiyaboonchai W, Tungpradit W, Plianbangchang P. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int. J. Pharm., 337, 299-306 (2007).
26. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur. J. Pharm. Sci., 37, 223-230 (2009).
27. Tsai YM, Jan WC, Chien CF, Lee WC, Lin LC, Tsai TH. Optimized nano-formulation on the bioavailability of hydrophobic polyphenol, curcumin, in freely-moving rats. Food Chem., 127, 918-925 (2011).
28. Anitha A, Deepagan VG, Divya Rani VV, Menon D, Nair SV, Jayakumar R. Preparation, characterization, in vitro drug release and biological studies of curcumin loaded dextran sulphate-chitosan nanoparticles. Carbohydr. Polym., 84, 1158-1164 (2011).
29. Bhawana, Basniwal RK, Buttar HS, Jain VK, Jain N. Curcumin nanoparticles: preparation, characterization, and antimicrobial study. J. Agric. Food Chem., 59, 2056-2061 (2011).
30. Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: A future nanomedicine for cancer. Drug Discov. Today, 17, 71-80 (2012).
31. Wu W, Shen J, Banerjee P, Zhou S. Water-dispersible multifunctional hybrid nanogels for combined curcumin and photothermal therapy. Biomaterials, 32, 598-609 (2011).
32. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med., 64, 353-356 (1998).
33. Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos., 27, 486-494 (1999).
34. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res., 21 (4B), 2895-2900 (2001).
35. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res., 10, 6847-6854 (2004).
36. Bass A, Stark JG, Pixton GC, Sommerville KW, Zamora CA, Leibowitz M, Rolleri R. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: A single-dose, randomized, open-label, 5-way crossover study in healthy volunteers. Clin. Ther., 34, 1601-1612 (2012).
37. Benziger DP, Kaiko RF, Miotto JB, Fitzmartin RD, Reder RF, Chasin M. Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediaterelease oxycodone solution. J. Pharm. Sci., 85, 407-410 (1996).
38. Wahlström B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol. Toxicol. (Copenh.), 43, 86-92 (1978).
39. Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica, 8, 761-768 (1978).
40. Graham A. Curcumin adds spice to the debate: lipid metabolism in liver disease. Br. J. Pharmacol., 157, 1352-1353 (2009).
41. Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin. Exp. Pharmacol. Physiol., 39, 283-299 (2012).
42. Gupta SC, Sung B, Kim JH, Prasad S, Li S, Aggarwal BB. Multitargeting by turmeric, the golden spice: From kitchen to clinic. Mol. Nutr. Food Res., 57, 1510-1528 (2013).
43. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": From kitchen to clinic. Biochem. Pharmacol., 75, 787-809 (2008).
44. Rong S, Zhao Y, Bao W, Xiao X, Wang D, Nussler AK, Yan H, Yao P, Liu L. Curcumin prevents chronic alcohol-induced liver disease involving decreasing ROS generation and enhancing antioxidative capacity. Phytomedicine, 19, 545-550 (2012).
45. Eybl V, Kotyzova D, Koutensky J. Comparative study of natural antioxidants - curcumin, resveratrol and melatonin - in cadmium-induced oxidative damage in mice. Toxicology, 225, 150-156 (2006).
46. Fu Y, Zheng S, Lin J, Ryerse J, Chen A. Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol. Pharmacol., 73, 399-409 (2008).
47. Kamalakkannan N, Rukkumani R, Varma PS, Viswanathan P, Rajasekharan KN, Menon VP. Comparative effects of curcumin and an analogue of curcumin in carbon tetrachloride-induced hepatotoxicity in rats. Basic Clin. Pharmacol. Toxicol., 97, 15-21 (2005).
48. Reyes-Gordillo K, Segovia J, Shibayama M, Vergara P, Moreno MG, Muriel P. Curcumin protects against acute liver damage in the rat by inhibiting NFkappaB, proinflammatory cytokines production and oxidative stress. Biochim. Biophys. Acta, 1770, 989-996 (2007).
49. Rukkumani R, Aruna K, Varma PS, Rajasekaran KN, Menon VP. Comparative effects of curcumin and an analog of curcumin on alcohol and PUFA induced oxidative stress. J. Pharm. Pharm. Sci., 7, 274-283 (2004).